Abraxis BioScience Gets SFDA Nod For Metastatic Breast Cancer Drug In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Abraxis BioScience received approval from China's State FDA to market its metastatic breast cancer drugAbraxane (paclitaxel albumin-bound particles for injectable suspension) in China, the company announced July 14